Redefining the discovery and development of best-in-class oligonucleotide therapeutics

Our Mission

With OligoCreator®, our AI-empowered drug discovery platform, we deliver on our mission to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.

About Us

We develop cutting-edge oligonucleotide therapies, that go beyond the reach of existing treatments and offer new hope to patients around the world.

Our Science

OligoCreator, our AI-empowered drug discovery platform, combines both innovative and proven delivery modalities with the precision and specificity of oligonucleotides.

Partnering

Global partner of choice for oligonucleotide drug discovery and development programs.

Pipeline

Innovative treatment options for indications where oligonucleotide-based therapeutics have the potential to be first-in-class or best-in-class.

About us

We redefine the discovery and development of best-in-class oligonucleotide therapeutics. With our AI-empowered OligoCreator® platform, which integrates a variety of delivery technologies, we identify and characterize oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By precisely delivering these novel therapeutics to specific cells, organs or tissues, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Our unique OligoCreator® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.

Latest News & Events

all news

all events

May 12, 2025

Secarna Pharmaceuticals and Curie.Bio Portfolio Company Enter into Research and Option Agreement

Martinsried (Munich), Germany, May 12, 2025 – Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced the signing of a research and option agreement for a scientific and strategic collaboration with one of Curie.Bio’s portfolio companies.

April 28, 2025

Secarna Pharmaceuticals adds leading expert to Scientific Advisory Board with appointment of Prof. Dr. Vignali

Prof. Dr. Dario A.A. Vignali brings vast knowledge from groundbreaking cancer research work in immune regulation and the immunosuppressive tumor microenvironment
His expertise in the field of immuno-oncology and in particular NRP1, the target of Secarna’s lead asset, SECN-15, will help translate the Company’s scientific discoveries into significant clinical strategies
Prof. Vignali joins current SAB members Prof. Dr. Alexander M.M. Eggermont and Prof. Dr. Alfred Zippelius, both cancer research key opinion leaders

March 26, 2025

Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 as monotherapy and in combination with immune checkpoint inhibitors at AACR

Data will showcase SECN-15’s potential to significantly improve the efficacy of immune checkpoint inhibitors
Secarna is preparing for first-in-human trials to start mid-2026 to further explore this promising combination therapeutic strategy

April 28 - 30, 2025

LSX World Congress Europe

London, UK

With our AI-empowered OligoCreator® platform we streamline the identification and characterization of best-in-class oligonucleotide therapies to deliver transformative treatments and hope to patients in need by pushing the boundaries of medical science and transforming lives for the better.

Konstantin Petropoulos, Ph.D., MBA
CEO